Lifecore Biomedical, Inc.

NasdaqGS LFCR

Lifecore Biomedical, Inc. Operating Income for the Trailing 12 Months (TTM) ending November 24, 2024: USD -10.78 M

Lifecore Biomedical, Inc. Operating Income is USD -10.78 M for the Trailing 12 Months (TTM) ending November 24, 2024, a 50.85% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Lifecore Biomedical, Inc. Operating Income for the Trailing 12 Months (TTM) ending November 26, 2023 was USD -21.93 M, a -1.87% change year over year.
  • Lifecore Biomedical, Inc. Operating Income for the Trailing 12 Months (TTM) ending November 27, 2022 was USD -21.53 M, a -215.10% change year over year.
  • Lifecore Biomedical, Inc. Operating Income for the Trailing 12 Months (TTM) ending November 30, 2021 was USD -6.83 M, a 83.75% change year over year.
  • Lifecore Biomedical, Inc. Operating Income for the Trailing 12 Months (TTM) ending November 30, 2020 was USD -42.06 M, a -693.06% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
NasdaqGS: LFCR

Lifecore Biomedical, Inc.

CEO Mr. Paul Josephs
IPO Date Feb. 15, 1996
Location United States
Headquarters 3515 Lyman Boulevard
Employees 524
Sector Health Care
Industries
Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

Similar companies

AKAN

Akanda Corp.

USD 1.53

-6.13%

IRWD

Ironwood Pharmaceuticals, Inc.

USD 3.65

-3.18%

DERM

Journey Medical Corporation

USD 3.73

-1.32%

CPIX

Cumberland Pharmaceuticals Inc.

USD 2.67

14.59%

StockViz Staff

January 15, 2025

Any question? Send us an email